Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 28;8(2):e001038. doi: 10.1136/jitc-2020-001038

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

RFA in combination with sunitinib suppressed tumor growth and extended the life span of tumor-bearing mice. (A) Schematic diagram of the treatments. Mice with size-matched tumors were randomly distributed into four groups and respectively received no treatment, RFA monotherapy, sunitinib monotherapy, or combinational treatment with RFA and sunitinib. The tumor progression was monitored by MRI. (B) Tumor growth over the period of the 3-month treatment. MRI was used to monitor tumor growth, and ImageJ was used to quantitate tumor size. n=7 for the control mice without treatment, n=6 for the mice with RFA monotherapy, n=7 for the mice with sunitinib (SU) monotherapy, n=7 for the mice with the combinational treatment. Error bars represent means±SD. Statistical analysis was performed by Student t-test (Prism8). *p<0.05 indicates statistical significance. (C) Kaplan-Meier survival analysis. The number of survival mice in each group was counted every day. n=14 in the control mice without treatment, n=14 for the mice with RFA monotherapy, n=14 for the mice with sunitinib monotherapy, n=13 for the mice with combinational treatment. Statistical analysis was performed by log-rank (Mantel-Cox) test (Prism8), **p<0.01.